Advertisement

Updated

Viking shares surge after fatty liver drug trial

By Tamara Mathias (Reuters) – Viking Therapeutics Inc’s shares more than doubled in value on Tuesday after promising data from a mid-stage trial of its fatty liver drug were seen as topping that from larger rival...

Read More

For latest news and updates
Email-id is invalid